Skip to main content

SLDB

Stock
Health Care
Biotechnology

Performance overview

SLDB Price
Price Chart

Forward-looking statistics

Beta
1.55
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

solid biosciences (solid) is a cambridge, ma based biotech company singularly focused on developing treatments and cures for duchenne muscular dystrophy (dmd). solid combines sharp commercial focus with world-class science to advance promising therapies and is positioned to catalyze therapeutic development across all aspects of the disease. condition-focused, our mandate is comprehensive; improving daily life for patients and attacking the roots of dmd.

Company info

SectorHealth Care
IndustryBiotechnology
Employees111
Market cap$309.3M

Fundamentals

Enterprise value$94.2M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity8.02

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$3.01
Dividend per share
Revenue per share
Avg trading volume (30 day)$9M
Avg trading volume (10 day)$12M
Put-call ratio

Macro factor sensitivity

Growth+3.0
Credit+3.5
Liquidity-1.4
Inflation+0.8
Commodities-0.3
Interest Rates-2.3

Valuation

Dividend yield0.00%
PEG Ratio-1.83
Price to sales
P/E Ratio-1.83
Enterprise Value to Revenue
Price to book1.32

Upcoming events

Next earnings dayMay 16, 2025
Next dividend day
Ex. dividend day

News

SLDB Stock Rallies 60% in a Month: Here's What You Should Know

Solid Biosciences stock soars 60% in a month after the company announced positive initial data from its phase I/II DMD study of SGT-003.

Zacks Investment Research (March 7, 2025)
Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data

On Tuesday, Solid Biosciences Inc. SLDB released initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy.

Benzinga (February 18, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free